ArticlePDF Available

Abstract and Figures

Cervical cancer is one of the most common cancers among women worldwide. Current standards of care for cervical cancer includes surgery, radiation, and chemotherapy. Conventional chemotherapy fails to elicit therapeutic responses and causes severe systemic toxicity. Thus, developing a natural product based, safe treatment modality would be a highly viable option. Curcumin (CUR) is a well-known natural compound, which exhibits excellent anti-cancer potential by regulating many proliferative, oncogenic, and chemo-resistance associated genes/proteins. However, due to rapid degradation and poor bioavailability, its translational and clinical use has been limited. To improve these clinically relevant parameters, we report a poly(lactic-co-glycolic acid) based curcumin nanoparticle formulation (Nano-CUR). This study demonstrates that in comparison to free CUR, Nano-CUR effectively inhibits cell growth, induces apoptosis, and arrests the cell cycle in cervical cancer cell lines. Nano-CUR treatment modulated entities such as miRNAs, transcription factors, and proteins associated with carcinogenesis. Moreover, Nano-CUR effectively reduced the tumor burden in a pre-clinical orthotopic mouse model of cervical cancer by decreasing oncogenic miRNA-21, suppressing nuclear β-catenin, and abrogating expression of E6/E7 HPV oncoproteins including smoking compound benzo[a]pyrene (BaP) induced E6/E7 and IL-6 expression. These superior pre-clinical data suggest that Nano-CUR may be an effective therapeutic modality for cervical cancer.
Content may be subject to copyright.
Scientific RepoRts | 6:20051 | DOI: 10.1038/srep20051
Curcumin Nanoformulation for
Cervical Cancer Treatment
Mohd S. Zaman
, Neeraj Chauhan
, Murali M. Yallapu
, Rishi K. Gara
, Diane M. Maher
Sonam Kumari
, Mohammed Sikander
, Sheema Khan
, Nadeem Zafar
, Meena Jaggi
Subhash C. Chauhan
Cervical cancer is one of the most common cancers among women worldwide. Current standards of care
for cervical cancer includes surgery, radiation, and chemotherapy. Conventional chemotherapy fails
to elicit therapeutic responses and causes severe systemic toxicity. Thus, developing a natural product
based, safe treatment modality would be a highly viable option. Curcumin (CUR) is a well-known
natural compound, which exhibits excellent anti-cancer potential by regulating many proliferative,
oncogenic, and chemo-resistance associated genes/proteins. However, due to rapid degradation
and poor bioavailability, its translational and clinical use has been limited. To improve these clinically
relevant parameters, we report a poly(lactic-co-glycolic acid) based curcumin nanoparticle formulation
(Nano-CUR). This study demonstrates that in comparison to free CUR, Nano-CUR eectively inhibits cell
growth, induces apoptosis, and arrests the cell cycle in cervical cancer cell lines. Nano-CUR treatment
modulated entities such as miRNAs, transcription factors, and proteins associated with carcinogenesis.
Moreover, Nano-CUR eectively reduced the tumor burden in a pre-clinical orthotopic mouse model
of cervical cancer by decreasing oncogenic miRNA-21, suppressing nuclear β-catenin, and abrogating
expression of E6/E7 HPV oncoproteins including smoking compound benzo[a]pyrene (BaP) induced
E6/E7 and IL-6 expression. These superior pre-clinical data suggest that Nano-CUR may be an eective
therapeutic modality for cervical cancer.
Cervical cancer is one of the most common and deadly cancers among women worldwide and is associated with
persistent Human Papillomavirus (HPV) infection
. Only a small subset of women with chronic HPV infection
progresses to develop the disease
. Additional factors are needed to acquire an immortal phenotype and to fur-
ther advance towards malignant and invasive phenotypes
. In addition to HPV infection, cigarette smoking and
smoke carcinogen (benzo[a]pyrene, BaP), are known risk factors associated with cervical cancer
. Viral mor-
phogenesis is increased subsequent to BaP treatment of cells infected with the high-risk HPVs, 31, 16 and 18 in
organotypic ra cultures derived from a cervical intraepithelial neoplasia type I cell line
. Moreover, micro RNAs
(miRNAs), small noncoding RNAs that regulate the expression of protein-coding genes, also play an impor-
tant role in the development of carcinogenesis. Resistance to chemo/radio-therapies with prolonged treatment,
resulting in an invasive form of cancer, requires the development of novel therapeutic modalities to conquer
chemo-resistance and improve the overall life expectancy of patients.
Curcumin (CUR) is a natural polyphenol compound that is derived from the rhizome of the medicinal plant
Curcuma longa Linn. It has been widely used in traditional Indian medicine for its ecacy against inammation,
respiratory diseases and other disorders
. Due to its anti-inammatory and anti-carcinogenic qualities, it has
also been extensively studied in the eld of cancer therapeutics. CUR has shown dose-dependent chemopreven-
tive and chemotherapeutic eects in a number of studies and pre-clinical trials
. Curcumin exhibits cytotoxic
eects in cervical cancer cells in a concentration-dependent and time-dependent manner and its activity was
found to be higher in HPV infected cells
. Curcumin has been proven to downregulate HPV18 transcription by
selectively inhibiting AP-1 activity, which reverses the expression dynamics of c-fos and fra-1 in cervical cancer
. Superior inhibitory action of curcumin against cervical cancer cells
was due to the inhibition of tel-
omerase activity, Ras, and ERK signaling pathways, cyclin D1, COX-2 and iNOS activity, and the mitochondrial
pathway. Interestingly, curcumin acted upon multiple targets and due to pretreatment was in turn able to revert
Department of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science
Center, Memphis, Tennessee, 38163, USA.
Cancer Biology Research Center, Sanford Research, Sioux Falls,
South Dakota, 57104, USA.
Department of Pathology, University of Tennessee at Memphis, Memphis, TN, USA.
Correspondence and requests for materials should be addressed to S.C.C. (email:
Received: 04 November 2015
Accepted: 23 December 2015
Published: 03 February 2016
Scientific RepoRts | 6:20051 | DOI: 10.1038/srep20051
the proliferative eects of cervical cancer cells. A recent proteomic study suggests that curcumin induces signif-
icant changes in tumor-related proteins that are associated with cell metabolism, cell cycle, and carcinogenicity
in HeLa cells
. Additionally, curcumin acts as a sensitizer for chemotherapy and radiation in cervical cancer
therapy. We reported a detailed cellular suppressive mechanistic role of curcumin in a three-dimensional cervi-
cal cancer ra culture system
. Our study demonstrated that curcumin inhibited cell motility, induced apopto-
sis, decreased the expression of HPV oncoproteins, and restored tumor suppressor proteins. At present, about
55 clinical trials are listed on related to curcumin and cancer therapy (as of December 2, 2015),
which suggest its translational and clinical potential. Furthermore, it has demonstrated no toxicity to healthy
organs at higher doses such as 8 g/day in clinical trials
. However, it suers from very low systemic bioavailability,
poor pharmacokinetics, poor absorption ability, high metabolic rate, inactivity of metabolic products, together
with rapid elimination and clearance from the body
. Some studies have shown that a trace amount of CUR
was detected in the serum of humans when 4–12 g/day of CUR was administered
. Although curcumin has
inspired considerable interest for its extensive physiological activities, its poor bioavailability restricts its clinical
Nanoparticle technology provides an eective way to deliver anti-cancer drug(s) into tumors
. To circumvent
curcumins inherent issues, our lab has developed a curcumin nanoparticle formulation (Nano-CUR), (Fig.1A,B)
based on poly(lactic-co-glycolic acid) (PLGA), an FDA approved polymer. is formulation has shown to be
Figure 1. Nano-CUR improves cellular accumulation of curcumin in cervical cancer cells. (A) Structural
components of Nano-CUR formulation. (B) Representative transmission electron microscopy image of Nano-
CUR particles. (C) Fluorescent images of live cells showing increased uptake of CUR/Nano-CUR with increase
in dose. Original magnication 200X. (D) Samples were analyzed by ow cytometry for cellular uptake. Fold
change in mean uorescence normalized to the respective vehicle controls. Error bars show SEM; N = 3, average
of 3 independent experiments, done in triplicate; *p < 0.05.
Scientific RepoRts | 6:20051 | DOI: 10.1038/srep20051
eective for improved therapeutic eects in metastatic ovarian and breast cancer cells
. e objective of this
study was to implement this ecient Nano-CUR formulation to achieve improved anti-cancerous eects on cer-
vical cancer. Our results indicated that Nano-CUR eectively inhibited growth of cervical cancer cells (Caski
and SiHa), induced apoptosis, and arrested cell cycle in the G1-S transition phase. Moreover, Nano-CUR formu-
lation eectively reduced the tumor burden in NOD SCID gamma (NSG) orthotopic xenogra mouse model.
Additionally, Nano-CUR treatment caused a marked decrease in the levels of miRNA-21 (an onco-miRNA asso-
ciated with chemo-resistance), in in vitro and in vivo models
, and enhanced the expression of miRNA-214 (a
tumor suppressor)
, when compared to free CUR, besides decreasing the levels of IL-6 (Interleukin-6) cytokine
expression which was found to be enhanced with BaP treatment. Altogether, these results suggest that Nano-CUR
provides a benecial approach for a rational strategy to widen the chemo-preventive and therapeutic modality for
the overall management of cervical cancer.
Internalization of Nano-CUR in cervical cancer cells. e ecient internalization of drug mole-
cules contributes to their improved anti-cancer activity. To examine this phenomenon, we selected two HPV
infected cervical cancer cell lines (Caski and SiHa) as our in vitro model. SiHa cells have 1–2 copies of integrated
HPV 16
. Caski cells are a robust model of HPV because they contain about 600 copies of integrated HPV 16
Fluorescence microscopy and ow cytometry techniques were used to examine the internalization patterns of
CUR and Nano-CUR. e internalization was found to increase with an increase in the concentration of CUR
and Nano-CUR in Caski and SiHa cervical cancer cells (Fig.1C,D). Fluorescence microscopy analysis revealed
that cells incubated with free CUR exhibited presence of CUR in the periphery and cytoplasm (Fig.1C). Whereas,
in the case of Nano-CUR, internalization was more ecient by endocytosis process due to smaller size, and there-
fore, greater accumulation of CUR was observed on the cell membrane and cytoplasm (Fig.1C). is could be
due to the result of greater interaction of Nano-CUR with the cell surface. is eect might aid internalization of
the drug. A similar improved uptake of Nano-CUR was observed in the ow cytometry analyses (Fig.1D).
Nano-CUR inhibits growth of cervical cancer cells. To assess the anti-cancer potential of CUR and
Nano-CUR in cervical cancer, Caski and SiHa cells were treated with 10, 20, and 25 μ M CUR or Nano-CUR
for 48 hrs. Both cell lines showed an inhibitory eect of CUR/Nano-CUR on cellular proliferation, especially at
higher concentrations (20 and 25 μ M) (Fig.2A). To determine the long-term eect of CUR/Nano-CUR on the
growth of cervical cancer cells, we performed a colony formation assay (Fig.2B,C). Nano-CUR was found to be
more eective as compared to free CUR in reducing the clonogenic ability of cervical cancer cells (Fig.2B,C).
Nano-CUR inhibits cell cycle and induces apoptosis. To elaborate functional eects of CUR and
Nano-CUR on cervical cancer, Caski and SiHa cells were treated with varied concentrations of CUR, Nano-CUR
and their respective vehicle controls (DMSO and PLGA NPs) for 24 hrs as described in Methods. Aer 24 hrs, cells
were trypsinized and processed for ow cytometry analyses for cell cycle and apoptosis. CUR and Nano-CUR
were found to arrest Caski and SiHa cells in the G1-S transition phase (Fig.3A). e eect was more pronounced
at higher concentrations. Nano-CUR was found to be more eective in comparison to free CUR in inducing
apoptosis in Caski and SiHa cells (Fig.3B).
Nano-CUR eectively inhibits tumor growth in NOD SCID gamma (NSG) orthotopic xeno-
graft mouse model. An orthotopic mouse model was developed and used to assess the ecacy of CUR
and Nano-CUR to inhibit tumor growth in NSG mice. For that, Caski cells were injected directly into the cervix
of NSG mice. Following tumor development (~200 mm
), the mice were administered with intra-tumoral injec-
tions of CUR, Nano-CUR and their respective vehicle controls (PBST and PLGA NPs, respectively). Figure4A
illustrates the mice treated with various treatment groups. e tumor volumes were measured and presented on
the days shown in Fig.4B,C. At the termination of the experiment, mice were euthanized, interestingly CUR and
Nano-CUR treatment (Fig.4B,C) demonstrated inhibition of tumor growth over their respective control groups.
However, Nano-CUR treatment was found to be more eective than all other treatment groups. Average tumor
volume in all groups are as follows: Nano-CUR (637 ± 68 mm
) < CUR (816 ± 94 mm
) < PLGA NPs (control
NPs; 1042 ± 166 mm
) < PBST (1115 ± 184 mm
) (Fig.4B,C).
Nano-CUR eectively represses the expression of HPV oncoproteins in tumor tissues. HPV
oncoproteins, E6/E7, initiate the dysregulation of cellular proliferation and apoptotic mechanisms by targeting
p53 and retinoblastoma (Rb) tumor suppressor proteins, respectively
. is leads to oncogenesis and the devel-
opment of cervical carcinoma. Also, higher expression of Ki67, a commonly used marker for cell proliferation, is
associated with high-grade cervical intraepithelial neoplasia (CIN)
. Immunohistochemistry done on the tissue
slides made from the orthotopically generated mice tumors treated with CUR/Nano-CUR, and their respective
controls, revealed that Nano-CUR was more eective in suppressing E6/E7 and Ki67 expression levels in mice
tumors when compared with free CUR (Fig.4D).
Nano-CUR efficiently modulated BaP induced expression of miRNAs in cervical cancer
cells. As mentioned earlier, in addition to HPV infection, cigarette smoking and smoke carcinogens, such as
benzo[a]pyrene (BaP), are known risk factors for cervical cancer. Our prior work has shown that BaP increased
the level of HPV oncoproteins, E6/E7
. us, Caski cells were treated with BaP alone and in combination with
CUR and Nano-CUR. BaP was found to increase the expression of oncogenic miRNA-21 and decrease the expres-
sion of the tumor suppressor miRNA-214 which was abrogated by CUR/Nano-CUR treatment. is indicates
that CUR and Nano-CUR treatments can mitigate the oncogenic eects of BaP by decreasing the expression of
Scientific RepoRts | 6:20051 | DOI: 10.1038/srep20051
miRNA-21 and increasing the expression of the tumor suppressor miRNA-214. Nano-CUR treatment however,
was found to be more eective than free CUR in inducing these eects (Fig.5A,B).
Nano-CUR inhibits BaP induced IL-6 expression in cervical cancer cells. Previous studies have
shown that the IL-6 induces the expression of miRNA-21 in cancer cells
. us, we sought to investigate the eect
of BaP on IL-6 in Caski cells. BaP was found to increase the IL-6 expression as compared to its vehicle control.
CUR and Nano-CUR were observed to decrease the oncogenic eects of BaP by decreasing the expression of
IL-6. Again, Nano-CUR was more eective than free CUR at similar concentrations in decreasing IL-6 expression
Restoration of anti-survival pathways aected by BaP through Nano-CUR. miRNA-21 is asso-
ciated with several cancers and involved in chemoresistance and metastasis. It is also responsible for activat-
ing a number of pro-survival pathways
. To determine mechanisms that are involved in enhanced expression
of miRNA-21, we investigated the modulations of several transcription factors and proteins that are related to
miRNA-21. Western blot studies indicated that BaP treatment induced activation of transcription factors STAT-3
Figure 2. CUR/Nano-CUR inhibit proliferation and clonogenic potential of cervical cancer cells.
(A) Proliferation was determined using MTS method with Caski and SiHa cell lines. Results were normalized
to control wells treated with appropriate amounts of vehicle, DMSO for CUR and PLGA for Nano-CUR.
Error bars show SEM; N = 3, average of 3 independent experiments, done in replicates of 6; *p < 0.05.
(B,C) Clonogenic potential was performed with Caski and SiHa cells. (B) Representative colony formation
images of cervical cancer cells upon treatment. (C) Inhibitory eect of treatments measured by colony counting.
Graphs represent average of three independent experiments, each replicated three times; *p < 0.05.
Scientific RepoRts | 6:20051 | DOI: 10.1038/srep20051
and STAT-5 (i.e., increased the phosphorylated form of STAT-3 and STAT-5), and NF-kB (Fig.5D). BaP was
also responsible for decreasing the expression of the anti-survival phosphatase PTEN, a direct target of miRNA-
, in addition to increasing the inactive form of PTEN, phospho-PTEN (p-PTEN)
. CUR and Nano-CUR
were observed to mitigate the oncogenic eects of BaP by reducing the expression of phosphorylated forms of
STAT-3 and STAT-5, and decreasing NF-κB. Moreover, they also increased the expression of PTEN and reduced
the inactivated form of PTEN, p-PTEN (Fig.5D). CUR and Nano-CUR were also instrumental in decreasing the
cytoplasmic amount of β -catenin, which is a direct target of miRNA-214
In vivo assessment of miRNA-21 and its direct target, PTEN, in mice tissues treated with CUR/
Nano-CUR. To examine the in vivo eects of CUR and Nano-CUR on miRNA expression, we investigated
the expression of miRNA-21 in mice tumors treated with CUR, Nano-CUR and their respective vehicle controls.
In situ hybridization of miRNA-21 in mice tumor tissues showed that CUR and Nano-CUR eectively reduced
miRNA-21 expression as compared to their respective controls. Additionally, immunohistochemical analysis
showed that CUR and Nano-CUR signicantly enhanced the expression levels of PTEN, which is a direct target
for miRNA-21 and a well-known tumor suppressor (Fig.5E).
Nano-CUR reduces BaP and IL-6 enhanced migration of cervical cancer cells. Previous studies
have shown that BaP enhances cell motility through dierent mechanisms in cancer cells
. BaP alone was
observed to increase cell migration in Caski and SiHa cells. IL-6 further enhanced the motility of the cells in
combination with BaP. CUR and Nano-CUR were found to eectively reduce BaP and IL-6 mediated enhanced
cellular motility of these cells (Fig.6A).
Figure 3. Eect of CUR and Nano-CUR on cell cycle and apoptosis in cervical cancer cells. (A) CUR/Nano-
CUR treatment arrests Caski and SiHa cells at the G1-S transition. Cervical cancer cells were treated with CUR/
Nano-CUR for 24 hrs. Samples were analyzed by ow cytometry for cell cycle analysis. Error show SEM; N = 3,
average of 3 independent experiments, done in triplicate. (B) CUR/Nano-CUR treatment induces apoptosis in
Caski cervical cancer cell line. Flow cytometry was done to detect the early apoptosis (Annexin V +ve) or late
apoptosis (Annexin V +ve and 7AAD +ve).
Scientific RepoRts | 6:20051 | DOI: 10.1038/srep20051
Nano-CUR suppresses BaP induced nuclear translocation of β-catenin. β -catenin is a key medi-
ator of Wnt signaling, and its deregulation, resulting in its nuclear accumulation, which in turn can cause cancer
progression and metastasis
. In normal cells, β -catenin is anchored at the plasma membrane with E-cadherin,
and is maintained at low levels in the cytoplasm by an APC/axin-dependent degradation complex. Mutations
occurring in β -catenin itself or its degradation complex proteins result in the inability to degrade β -catenin,
which leads to the increase of protein levels of β -catenin that accumulate in the nucleus
. us it binds to the
members of LEF-1/TCF family of transcription factors, subsequently resulting in stimulation of gene expres-
sion and production of proteins involved in cell transformation
. erefore, persistent nuclear localization
of β -catenin is the key initiating and driving event for transformation of normal (non-tumor) cell to tumor cell.
Treatment with BaP resulted in an increase in the nuclear translocation of β -catenin in comparison to control as
evidenced through confocal microscopy (Fig.6B). Nano-CUR treatment was found to be more eective than free
Figure 4. Nano-CUR signicantly reduces tumor growth and oncogenic HPV E6/E7 and Ki67 proteins in
cervical cancer orthotopic mouse model. Tumor formation in female nude mice by injecting 4 million Caski
cells. (AC) Nano-CUR was able to reduce the tumor burden by a considerable amount as compared to free
CUR. Error bars show SEM; N = 6; *p < 0.05. (D) Immunohistochemical (IHC) analysis showed that CUR
and Nano-CUR were eective in suppressing the expression of HPV oncogenic proteins E6 and E7 and cell
proliferation marker Ki67 in mice. Original magnication 400X.
Scientific RepoRts | 6:20051 | DOI: 10.1038/srep20051
CUR, especially at higher concentrations, in reducing nuclear β -catenin accumulation and enhancing β -catenin
translocation to the plasma membrane.
Cervical cancer is the third most common cancer in women worldwide
. Invasive cervical cancer and the
precursor lesions are the result of persistent infection by oncogenic HPVs, predominantly HPV types 16, 18,
31, etc.
. However, HPV infection only is not enough to immortalize and transform the epithelial cells of the
host. Additional co-factors are needed to acquire an immortal phenotype and to further develop into a blatant
Figure 5. Eect of BaP, CUR and Nano-CUR on miRNAs, cytokine IL-6 expression and related pathways
in Caski cells. BaP was found to: (A) increase the expression of oncogenic miRNA-21, and (B) decrease
the expression of tumor suppressor miRNA-214. Nano-CUR was found to be more eective than free CUR
in mitigating the oncogenic eects of BaP, by decreasing miRNA-21 and increasing miRNA-214. (C) BaP
increased the expression of oncogenic IL-6, which was decreased eectively by CUR and Nano-CUR. (D) CUR
and Nano-CUR restore anti-survival pathways aected by BaP by suppressing oncogenic transcription factors
and restoring tumor suppressor PTEN. Control-DMSO + PLGA; BaP-Benzo(a)pyrene; CUR; Nano-CUR.
miRNA expression was assessed through qRT-PCR using Taqman primers and IL-6 expression was analyzed
using a cytokine assay kit. Western blotting was done using commercially available antibodies. e experiments
were done in triplicate. Error bars show SEM; N = 3; all concentrations are in μ M; *p < 0.05. (E) ISH (In situ
hybridization) of miRNA-21 and IHC of PTEN in mice tumor tissues treated with CUR and Nano-CUR.
Blue marks correspond to miRNA-21 and brown marks correspond to PTEN expression. ISH and IHC were
conducted according to the manufacturer’s protocol for FFPE tissues of control and treated orthotopic mice to
detect the expression of miRNA-21 and PTEN. Original magnication 200X.
Scientific RepoRts | 6:20051 | DOI: 10.1038/srep20051
malignant and invasive phenotype
. In addition to HPV infection, cigarette smoking is a known risk factor with
smoke carcinogens such as benzo[a]pyrene (BaP)
. BaP levels have been found to be elevated in the cervical
mucus of women who smoke
. BaP has been shown to stimulate high levels of the viral oncoproteins E6 and E7,
besides enhancing virion synthesis in cell lines prolically infected with HPV
. Furthermore, mixtures containing
BaP, such as cigarette smoke condensate, have been shown to induce remarkable microRNA alterations in rodent
lungs and in in vitro human bronchial models
Conventional cytotoxic chemotherapy/radiation therapy in patients with recurrent and metastatic cervical can-
cer is restricted due to the eventual development of drug resistance and systemic toxicity. erefore, it is imperative
to implement biologically safe and eective natural compounds as anti-cancer and chemopreventive drugs that
have already been widely used in humans and have fewer systemic side eects. One such promising molecule is cur-
cumin, a natural polyphenol compound found in turmeric. is molecule is widely studied in the literature ( > 8,350
peer-reviewed articles, = curcumin, search resulted on December 02,
2015) and has been used in more than 125 clinical trials ( = c urcumin&-
Search = Search, search resulted on December 02, 2015). is molecule has a number of pharmacological activities,
including anti-oxidant and anti-mutagen properties, and can inhibit the development of carcinogenesis. In our pre-
vious report, we demonstrated the anti-cancer eects and reversion of BaP-induced oncoproteins with curcumin
treatment in cervical cancer cells. Based on curcumins excellent pleiotropic properties, its clinical implication that
includes cancer treatments has increased signicantly in recent years. However, its inherent bioavailability and rapid
degradation characteristics restrict its use in clinical settings. erefore, our current study utilized a novel strategy to
treat cervical cancer with a curcumin nanoformulation, i.e., Nano-CUR (Fig.1A,B).
Figure 6. Eect of CUR and Nano-CUR on the suppression of BaP and IL-6 induced cellular migration.
(A) CUR and Nano-CUR were able to suppress BaP and IL-6 induced cellular migration in cervical cancer cells.
(B) Inhibition of enhanced nuclear translocation of β -catenin by BaP through CUR and Nano-CUR. For this
study, 80,000 Caski cells were seeded overnight in 4-well chamber slides, then treated with BaP alone and in
combination with CUR/Nano-CUR for 24 hrs. Subsequently, they were xed and processed for immunostaining
using anti β -catenin Ab. Confocal images are shown for nuclear staining (Blue for DAPI) and β -catenin (red for
Cy3), using a Nikon confocal microscope. Original magnication 200X.
Scientific RepoRts | 6:20051 | DOI: 10.1038/srep20051
Our data, for the rst time, demonstrated signicant accumulation of curcumin in cervical cancer cells
when we use the Nano-CUR formulation (Fig.1C,D). is indicates that curcumin nanoformulation uptake is
favored by superior endocytosis due to its smaller size. A similar enhanced cellular uptake was observed even
in other types of cancer cells
. Such internalization leads to pronounced eects due to the drugs. As expected,
we observed Nano-CUR to be more eective in reducing cell viability and clonogenicity of cervical cancer cells
(Fig.2). Furthermore, the superior functional eects of Nano-CUR was conrmed through ow cytometry by
performing cell cycle and apoptosis assays. Nano-CUR was observed to be more eective in arresting cells in
G1-S transition as compared to free CUR at higher concentrations (Fig.3A). Additionally, Nano-CUR was found
to be more eective in comparison to free CUR in inducing apoptosis in cervical cancer cells, wherein it induced
63–88% late apoptosis at higher concentrations (Fig.3B).
To further verify the improved therapeutic ecacy of the Nano-CUR formulation, we generated an ortho-
topic mouse model of cervical cancer (Caski cells) using NSG mice. Nano-CUR treatment was more eective
to inhibit the tumor growth over all other groups (Fig.4B,C). is demonstrates that curcumin showed better
therapeutic eects in its nanoformulation form (Fig.4). Previous studies from our lab
have shown that curcumin
decreases the expression of the oncogenic HPV protein E7 in in vitro models. is led us to conrm the status of
HPV oncogenic proteins E6 and E7 in NSG mice tumor tissues that were collected aer the treatment. CUR and
Nano-CUR treatment eectively suppressed the expression of E6 and E7 oncoproteins. Nano-CUR, however, was
more ecient than free CUR in decreasing the expression levels of Ki67, a well-known marker for cell prolifera-
tion (Fig.4D).
Furthermore, the anti-oncogenic eects of CUR and Nano-CUR were measured against smoke carcinogen,
BaP. e cancer causing eects of BaP, such as increasing the expression of oncogenic entities miRNA-21 and IL-6
and decreasing the expression of the tumor suppressor miRNA-214, were mitigated by CUR and Nano-CUR.
ese eects were even more signicant with Nano-CUR treatment (Fig.5A–C). CUR/Nano-CUR were also
eective in restoring the anti-survival pathways aected by BaP treatment through decreasing the expression
of oncogenic transcription factors such as p-STAT3/5, NF-κ B and β -catenin and enhancing the expression of
the tumor suppressor phosphatase PTEN, besides suppressing its inactive form p-PTEN (Fig.5D). Polycyclic
aromatic hydrocarbons like BaP or its derivatives are known to increase the expression of pro-inammatory
cytokines such as IL-8 or IL-6
in various organs and cancers. IL-6 mediated activation of transcription factor
STAT3 (to its activated form p-STAT3) is a common oncogenic process and is one of the mechanisms through
which chronic inammation contributes to cancer development and progression
. Previous studies have demon-
strated that an upstream enhancer that contains two STAT3 binding sites controls the gene encoding miRNA-21
and miRNA-21 expression is dependent on binding of the activated form of STAT3 (p-STAT3) to its promoter
. Moreover, these studies also show that miRNA-21 gene transcription is controlled by IL-6 and entails
STAT3. e overexpression of miRNA-21 has been observed in several cancers and all of those cancers have
constitutively activated STAT3 (p-STAT3)
. Furthermore, NF-κ B has also been shown to increase miRNA-21
expression in a number of studies
. All of this corroborates our nding in cervical cancer that BaP treatment
leads to an increase in miRNA-21 expression. Additionally, CUR and Nano-CUR restore the expression of the
tumor suppressor phosphatase PTEN, a direct target of miRNA-21 (Fig.5A,D). We also validated the expression
levels of miRNA-21 and PTEN in mice tumors generated through the establishment of the orthotopic model of
cervical cancer. In situ hybridization of the tissue slides showed that CUR and Nano-CUR were eective in abro-
gating the expression of miRNA-21 and thus increased expression of PTEN (Fig.5E). CUR and Nano-CUR were
also able to suppress IL-6 (Fig.5C) and BaP-induced migration of cervical cancer cells (Fig.6A). IL-6 is known
to enhance the cellular migratory properties of cancer cells
. Polycyclic aromatic hydrocarbons (PAHs) such
as BaP are also known to enhance cellular migration in several types of cells
. It would be interesting to see
if BaP alone or in combination with pro-inammatory cytokines such as IL-6 can lead to enhanced inamma-
tion which is a precursor of oncogenesis
. Additionally, Nano-CUR was found to be more eective than free
curcumin in suppressing nuclear translocation of β -catenin and restoring membrane bound β -catenin in Caski
cervical cancer cells (Fig.6B). Nuclear localization of β -catenin is the key initiating and driving event for transfor-
mation of normal (non-tumor) cell to tumor cell (as discussed in Results). Moreover, β -catenin is a direct target of
miRNA-214, a tumor suppressor miRNA in cervical cancer (as mentioned earlier in Results).
In conclusion, this study clearly is an advancement of an earlier report of curcumin nanoformulation tested
against cancer cells
. Our ndings show that PLGA based Nano-CUR signicantly inhibits growth of cervical
cancer cells and regulates the expression of miRNAs and various oncogenic and tumor suppressor proteins asso-
ciated with cervical cancer (Fig.7). In vivo experiments show that Nano-CUR is ecacious in reducing the tumor
burden. erefore, Nano-CUR may be a novel chemo-preventive and therapeutic modality for the management
of cervical cancer.
Materials and Methods
Cell Culture. Caski and SiHa cervical cancer cell lines were purchased from American Type Culture
Collection (Manassas, VA). ese cell lines were expanded and low passage frozen aliquots were stored in liquid
nitrogen. For conducting experiments, cells were thawed and grown for < 6 months. SiHa cells were maintained
in Dulbeccos Modied Eagles medium (DMEM) containing 4.5 g/L of glucose, 10 nM of nonessential amino
acids, 100 nM of sodium pyruvate, 1x antibiotic/antimycotic (Sigma, St. Louis MO), and 10% heat-inactivated
FBS (Atlanta Biologicals, Lawrenceville, GA). Caski cells were grown in Roswell Park Memorial Institute (RPMI)
medium containing 10% heat-inactivated FBS and 1x antibiotic/antomycotic. All cells were incubated in a
5% CO
incubator at 37 °C.
Preparation of Nano-CUR formulation. e PLGA based CUR nanoformulation was synthesized as
described previously
. Briey, 90 mg of PLGA solution in 10 mL of acetone was mixed with 10 mg of CUR for
Scientific RepoRts | 6:20051 | DOI: 10.1038/srep20051
5 min. is solution was added dropwise to 20 mL of aqueous solution containing 1% wt/vol PVA and 10 mg of
poly(l-lysine), over a period of 10 min on a magnetic stirrer at 800 rpm. e resulting suspension of Nano-CUR
particles was stirred at room temperature for ~24 hrs to evaporate the acetone solvent completely. Larger aggre-
gates and un-bound polymers were removed by centrifugation at 5000 rpm in an Eppendorf Centrifuge 5810 R
(Eppendorf AG, Hamburg, Germany) for 10 min. Nano-CUR particles were recovered by ultracentrifugation at
30,000 rpm using a Rotor 30.50 in an Avanti J-30I Centrifuge (Beckman Coulter, Fullerton, CA, USA). Particles
were washed twice and then freeze-dried using the Labconco Freeze Dry System ( 48 °C, 133 × 10
Labconco, Kansas City, MO). Control PLGA nanoparticles were similarly prepared by dissolving polymer in
organic solvent without CUR, with the rest of the method being the same.
Cellular uptake. To determine the uptake and internalization ecacy of Nano-CUR, we utilized uores-
cent microscopy and ow cytometry. For qualitative assessment, Caski and SiHa cells (2 × 10
cells/well in 2 mL
media) were plated in 6-well plates and allowed to attach overnight. Cells were then treated with 5, 10, and 20 μ M
CUR or Nano-CUR and their vehicle controls (DMSO and PLGA NPs, respectively) for 6 hrs. Aer 6 hrs, cells
were washed with PBS twice and replaced with phenol-red free medium. Live adherent cells were examined under
a uorescent microscope (Nikon Eclipse Ti Microscope, Melville, NY) and images were captured at 200X. For
quantitative measurement, cells (2 × 10
cells per well in 2 mL media) were plated in 6-well plates and allowed
to attach overnight. Cells were then treated with 5, 10, and 20 μ M CUR or Nano-CUR and their vehicle controls
(DMSO and PLGA-NPs, respectively) for 6 hrs. Aer 6 hrs, cells were washed with PBS, trypsinized, and collected
Figure 7. Schematic representation of CUR/Nano-CURs eect on the suppression of E6 and E7 HPV
proteins and IL-6 pathways to reduce the tumor burden in an orthotopic cervical cancer mouse model.
Scientific RepoRts | 6:20051 | DOI: 10.1038/srep20051
in 2 mL media. Further, these cells were centrifuged, washed with PBS twice, and collected in 2 mL phenol-red
free medium for ow cytometry analysis. About 10,000 cells in medium were injected into an Accuri C6 Flow
Cytometer (BD Biosciences, San Jose, CA, USA) to determine the uorescence levels in the FL1 channel (488
excitation, Blue laser, 530 ± 15 nm, FITC/GFP). FL1 channel measures the green uorescence generated by the
curcumin or Nano-CUR.
Cell proliferation assay. e eect of CUR and Nano-CUR on cell growth was determined by cell prolif-
eration assay using CellTiter96 Aqueous One Solution (MTS) reagent (Promega, Madison, WI). Briey, cervical
cancer cells (5000 cells/well) were plated in 100 μ L DMEM/RPMI medium in 96-well tissue culture plates and
incubated overnight. CUR was dissolved in DMSO and diluted in cell culture media. e cells were treated with
varying concentrations of CUR/Nano-CUR or equivalent amounts of vehicle controls (DMSO/PLGA) for 48 hrs.
Cell proliferation was determined by adding 20 μ L of MTS reagent, incubating for 2 hrs at 37 °C and measuring
the absorption at 490 nm using a SPECTRA Max Plus Plate Reader (Molecular Devices, Sunnyvale, CA). e
percent proliferation in CUR/Nano-CUR treated cells was determined by normalizing the cells with no treatment
(considered as 100%).
Colony forming assay. For this assay, cervical cancer cells were seeded at 500 cells per well in 2 mL media
in 6-well plate and allowed for 24 hrs to attach. Aer that, cells were treated with concentrations of 2.5, 5, and
10 μ M CUR/Nano-CUR for an additional 12–14 days. e cells were washed, xed in cold methanol, and stained
with hematoxylin. Visible colonies (~50 cells) were counted manually and reported as the ratio of the number of
colonies in treated cells divided by the number of colonies in the vehicle (DMSO/PLGA) control.
Cell cycle analysis. Cell cycle arrest was analyzed by the Telford method. Caski and SiHa cervical cancer
cells (1 × 10
) were plated in a 100 mm dish and allowed to attach overnight. e following day, cells were exposed
to either 10 or 25 μ M CUR, Nano-CUR or equivalent amounts of controls for 24 hrs, trypsinized, washed, xed
with 70% ethanol, stored at 4 °C for an hr, stained with propidium iodide (Sigma-Aldrich, St. Louis, MO; 50 μ g in
1 mL Telford reagent) in the dark for 4 hrs at 4 °C and analyzed by an Accuri C6 Flow Cytometer in FL2 channel.
Annexin V-7AAD staining. Detection of apoptosis was determined by using Annexin V-7AAD staining.
Caski and SiHa cervical cancer cells (1 × 10
) were plated in a 100 mm dish and allowed to adhere overnight. e
next day, cells were treated with 10, 20 and 25 μ M CUR, Nano-CUR or equivalent amounts of controls for 24 hrs.
At the end of indicated time, both adherent and oating cells were collected and stained with Annexin V and
7-AAD (BD Biosciences) at 5 μ L of each/100 μ L of cell suspension. Cells were incubated for 20 min in the dark at
room temperature and analyzed with an Accuri C6 Flow Cytometer in FL2 and FL3 channels.
Orthotopic model of cervical cancer in NSG mice. Six-week-old female NSG mice (Cancer Research
Animal Core, UTHSC, Memphis, TN) were used to generate an orthotopic model of cervical cancer. e mice
were maintained in a pathogen-free environment and all procedures were carried out as approved by the UTHSC
Institutional Animal Care and Use Committee (UTHSC-IACUC). All the procedures and methods were car-
ried out in “accordance” with the approved guidelines of UTHSC-IACUC. Briey, Caski cells (4 × 10
mouse) were dispersed in 100 μ L 1X PBS and 100 μ L Matrigel (BD Biosciences) and injected directly into the
cervix of the mice. e animals were periodically monitored for tumor development and the tumor volume was
measured from day 5 aer injection using a digital Vernier caliper. When the tumor volume reached ~200 mm
CUR, Nano-CUR (100 g/mice) and their respective vehicle controls (PBST and PLGA NPs, respectively) were
injected intra-tumorally. e tumor volume was calculated using the ellipsoid volume formula: tumor volume
) = π/6 × L × W × H, wherein L is length, W is width, and H is height. e tumor was regularly monitored
and allowed to grow until the tumor burden reached a maximum volume of 1100 mm
. At the time of sacrice,
the mice tumors were removed, xed in formalin, embedded in paran, and sliced into 5 micron sections for
further processing and analysis.
Reverse transcription quantitative real-time polymerase chain reaction (qRT-PCR). Caski
cervical cancer cells were seeded in a 6-well plate, allowed to attach, and treated with varied concentrations of
CUR/Nano-CUR and their vehicle controls (DMSO/PLGA) and BaP in their respective combinations for
4 days. Total RNA was extracted from treated cells using TRIzol reagent (Invitrogen, Life Technologies, Grand
Island, NY). e integrity of the RNA was measured with an RNA 6000 Nano Assay kit and 2100 Bioanalyzer
(Agilent Technologies, Santa Clara, CA). For miRNA detection, 100 ng total RNA was reverse transcribed into
cDNA using specic primers designed for miRNA analysis (Applied Biosystems, Foster City, CA). e miRNA
expression levels were determined by qRT-PCR using the Taqman PCR master mixture (no AmpErase UNG) and
specic primers designed for detection of mature miRNAs (Applied Biosystems). e expression of miRNA was
normalized with the expression of endogenous control, U6snRNA.
IL-6 measurement. Caski cervical cancer cells were treated using modified culture medium (RPMI-
1640 + 2% FBS). Briey, aer treatment with BaP alone or in combination (BaP and CUR/Nano-CUR) for 48 hrs,
culture medium was centrifuged at 10,000 g for 10 min at 4 °C. OD was measured at 450 nm. IL-6 (eBioscience,
San Diego, CA, USA) measurement was performed as per manufacturer’s instructions. Quantication of IL-6 was
performed by standard curve prepared by recombinant human IL-6 (provided with the kit) and normalized with
live cells. All experiments were performed in triplicate and repeated at least three times.
Scientific RepoRts | 6:20051 | DOI: 10.1038/srep20051
Migration assay. Cell migration assay was performed in Cornings 96-well HTS transwell as per manu-
facturer’s instructions with minor modications. Briey, Caski cells (50,000 cells/well) were seeded in upper
chambers of the plate containing serum-free culture medium. Cells were further treated with BaP alone, or in
combination (BaP and CUR/Nano-CUR) for 18 hrs. Cells were allowed to migrate from upper chamber (5% FBS)
towards lower chamber which has 10% FBS. Cells in the upper chamber were completely removed by cotton swab.
Cells were xed with 4% paraformaldehyde prepared in PBS for 30 min. ese cells were stained with Giemsa
stain and migrated cells were observed by using a light microscope. Migrated cells were counted in six random
elds of view and the experiments were performed in triplicate.
Western blotting. Actively growing Caski cervical cancer cells were used for Western blot analysis. Briey,
Caski cells were washed with ice-cold phosphate buer saline (PBS) and lysed in 2X radioimmunoprecipitation
assay (RIPA) buer aer the respective treatments. Protein content was analyzed using Nanodrop 2000 (ermo
Scientic, Wilmington, DE), and equivalent amount of protein samples were electrophoretically separated on
4–20% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels, and transferred to a pol-
yvinylidene diuoride (PVDF) membrane (Bio-Rad Laboratories, Hercules, CA). Following blocking with 5%
bovine serum albumin (BSA; 5 mL for one hour), the membranes were probed overnight at 4 °C for various pro-
teins using specic primary antibodies (all from Cell Signaling Technologies, Danvers, MA). e western blots
were incubated with HRP-labeled secondary antibody and the protein bands were developed using Lumi-Light
Plus chemiluminescent reagent (Roche, Indianapolis, IN).
Immunouorescence and Confocal Microscopy. Immunouorescence staining was performed to
determine the eect of BaP on the nuclear translocation of β -catenin. 80,000 Caski cells were seeded overnight in
4-well chamber slides (Nalgene Nunc Intl.., Rochester, NY), then treated with BaP alone and in combination with
CUR/Nano-CUR for 24 hrs. Subsequently, they were xed and processed for immunostaining. Briey, cells were
xed in 2% para-formaldehyde, permeabilized, blocked and then incubated with primary antibody, anti β -catenin
Ab (Cell Signaling Technologies). Following washing, cells were incubated with Cy3 labeled secondary antibody
(Jackson Immunoresearch Labs, Westgrove, PA). Aer further washing, the cover slips were mounted on glass
slides using aqueous anti-fade medium (Vector Laboratories, Burlingame, CA). Slides were examined under a
laser confocal microscope (Nikon Corporation).
In situ hybridization for miRNA-21. In situ hybridization was conducted according to the manufacturer’s
protocol for FFPE tissues of control and treated orthotopic mice to detect the expression of miRNA-21 using a
Biochain kit (Biochain, San Francisco, CA). DIG-labeled LNA oligonucleotides (Exiqon, Woburn, MA) were used
for overnight hybridization at 50 °C. e staining was carried out as per Exiqon user manual instructions. Briey,
aer deparanization, specimens were xed in 4% para-formaldehyde in DEPC-PBS for 20 min and subjected to
digestion using 2X standard saline citrate and 0.1% Triton-X for the next 25 min. Slides were pre-hybridized with
pre-hybridization solution for 4 hrs at 48 °C followed by hybridization of the slides with hybridization buer and
probe (Digoxigenin labeled) at 45 °C overnight. Aer stringent washing of slides with various grades of standard
saline citrate, the slides were blocked using 1X blocking solution provided in the kit. e tissues were subse-
quently incubated overnight with the AP-conjugated anti-digoxigenin antibody. e slides were washed twice
for 5 min with 1X Alkaline Phosphatase buer. e nal visualization was carried out with NBT/BCIP overnight
followed by nuclear fast red counterstaining. e slides were mounted, imaged and analyzed under ScanScope
XT/ XT2 system (Aperio, Vista, CA). All the reagents used for the assay were provided in the kit from Biochain.
Immunohistochemical analysis of cervical orthotopic tumors. IHC analysis for HPV E6/E7 pro-
teins, Ki67 and PTEN on formalin xed, paran embedded orthotopic mouse tumors (5 micron sections) was
performed. Briey, the tumor tissues were deparanized, rehydrated, treated with 0.3% hydrogen peroxide and
processed for antigen retrieval using a heat-induced technique. Following blocking with background sniper
(Biocare Medical, Concord, CA), the samples were processed for staining with E6 (Abcam, Cambridge MA),
E7 (Invitrogen), Ki67 and PTEN antibodies (Cell Signaling Technologies). e expression of these proteins was
detected using a MACH 4 Universal HRP Polymer detection kit (Biocare Medical) and 3,39-diaminobenzidine
(DAB substrate kit, Vector Laboratories, Burlingame, CA). The slides were counterstained with hematoxy-
lin, dehydrated, mounted with VectaMount (Vector Laboratories) and visualized using an Olympus BX 41
Microscope (Olympus Corporation, Japan).
Statistical analysis. Values were processed using Microsoft Excel 2007 software and presented as
mean ± standard error of the mean (S.E.M.). Statistical analyses were performed using an unpaired, two-tailed
student t-test. e level of signicance was set at *p < 0.05. All graphs were plotted using Origin 6.1 soware.
1. Clare, M. A. et al. Human papillomavirus DNA methylation as a potential biomarer for cervical cancer. Cancer Epidemiol
Biomarers Prev 21, 2125–2137 (2012).
2. Moore, E. E., War, J. D., Hopper, J. L., Erbas, B. & Garland, S. M. e roles of genetic and environmental factors on ris of cervical
cancer: a review of classical twin studies. Twin es Hum Genet 15, 79–86 (2012).
3. Zhen, S., Hu, C. M. & Bian, L. H. Glutathione S-transferase polymorphism interactions with smoing status and HPV infection in
cervical cancer ris: an evidence-based meta-analysis. PLoS One 8, e83497 (2013).
4. Au, W. W., Abdou-Salama, S., Sierra-Torres, C. H. & Al-Hendy, A. Environmental ris factors for prevention and molecular
intervention of cervical cancer. Int J Hyg Environ Health 210, 671–678 (2007).
5. Maher, D. M. et al. Curcumin suppresses human papillomavirus oncoproteins, restores p53, b, and PTPN13 proteins and inhibits
benzo[a]pyrene-induced upregulation of HPV E7. Mol Carcinog 50, 47–57 (2011).
6. Alam, S., Conway, M. J., Chen, H. S. & Meyers, C. e cigarette smoe carcinogen benzo[a]pyrene enhances human papillomavirus
synthesis. J Virol 82, 1053–1058 (2008).
Scientific RepoRts | 6:20051 | DOI: 10.1038/srep20051
7. ahman, I., Biswas, S. . & irham, P. A. egulation of inammation and redox signaling by dietary polyphenols. Biochem
Pharmacol 72, 1439–1452 (2006).
8. Tirey, N., aur, G., Vij, G., Curcumin & Chopra, . A diferuloylmethane, attenuates cyclosporine-induced renal dysfunction and
oxidative stress in rat idneys. BMC Pharmacol 5, 15 (2005).
9. Deeb, D. D. et al. Chemosensitization of hormone-refractory prostate cancer cells by curcumin to TAIL-induced apoptosis. J Exp
er Oncol 5, 81–91 (2005).
10. Nardo, L., Andreoni, A., Bondani, M., Masson, M. & Hjorth Tonnesen, H. Studies on curcumin and curcuminoids. XXXIV.
Photophysical properties of a symmetrical, non-substituted curcumin analogue. J Photochem Photobiol B 97, 77–86 (2009).
11. Prusty, B. . & Das, B. C. Constitutive activation of transcription factor AP-1 in cervical cancer and suppression of human
papillomavirus (HPV) transcription and AP-1 activity in HeLa cells by curcumin. Int J Cancer 113, 951–960 (2005).
12. Di Domenico, F., Foppoli, C., Coccia, . & Perluigi, M. Antioxidants in cervical cancer: chemopreventive and chemotherapeutic
eects of polyphenols. Biochim Biophys Acta 1822, 737–747 (2012).
13. Singh, M. & Singh, N. Molecular mechanism of curcumin induced cytotoxicity in human cervical carcinoma cells. Mol Cell Biochem
325, 107–119 (2009).
14. Singh, M. & Singh, N. Curcumin counteracts the proliferative eect of estradiol and induces apoptosis in cervical cancer cells. Mol
Cell Biochem 347, 1–11 (2011).
15. Madden, . et al. Proteomics-based approach to elucidate the mechanism of antitumor eect of curcumin in cervical cancer.
Prostaglandins Leuot Essent Fatty Acids 80, 9–18 (2009).
16. Cheng, A. L. et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-ris or pre-malignant lesions.
Anticancer es 21, 2895–2900 (2001).
17. Anand, P., unnumaara, A. B., Newman, . A. & Aggarwal, B. B. Bioavailability of curcumin: problems and promises. Mol Pharm
4, 807–818 (2007).
18. Shehzad, A., Wahid, F. & Lee, Y. S. Curcumin in cancer chemoprevention: molecular targets, pharmacoinetics, bioavailability, and
clinical trials. Arch Pharm (Weinheim) 343, 489–499 (2010).
19. Shehzad, A., han, S., Shehzad, O. & Lee, Y. S. Curcumin therapeutic promises and bioavailability in colorectal cancer. Drugs Today
(Barc) 46, 523–532 (2010).
20. Ireson, C. et al. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat
in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer es 61, 1058–1064
21. Shaih, J., Anola, D. D., Beniwal, V., Singh, D. & umar, M. N. Nanoparticle encapsulation improves oral bioavailability of
curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci 37,
223–230 (2009).
22. Yallapu, M. M., Gupta, B. ., Jaggi, M. & Chauhan, S. C. Fabrication of curcumin encapsulated PLGA nanoparticles for improved
therapeutic eects in metastatic cancer cells. J Colloid Interface Sci 351, 19–29 (2010).
23. Wang, W. et al. MicroNA-21 and the clinical outcomes of various carcinomas: a systematic review and meta-analysis. BMC Cancer
14, 819 (2014).
24. Garajova, I. et al. Molecular mechanisms underlying the role of microNAs in the chemoresistance of pancreatic cancer. Biomed es
Int 2014, 678401 (2014).
25. Wang, F., Liu, M., Li, X. & Tang, H. Mi-214 reduces cell survival and enhances cisplatin-induced cytotoxicity via down-regulation
of Bcl2l2 in cervical cancer cells. FEBS Lett 587, 488–495 (2013).
26. Qiang, . et al. Plexin-B1 is a target of mi-214 in cervical cancer and promotes the growth and invasion of HeLa cells. Int J Biochem
Cell Biol 43, 632–641 (2011).
27. Meissner, J. D. Nucleotide sequences and further characterization of human papillomavirus DNA present in the CaSi, SiHa and
HeLa cervical carcinoma cell lines. J Gen Virol 80(Pt 7), 1725–1733 (1999).
28. Adler, ., Ericson, T. & Bobrow, M. High sensitivity detection of HPV-16 in SiHa and CaSi cells utilizing FISH enhanced by TSA.
Histochem Cell Biol 108, 321–324 (1997).
29. Saavedra, . P., Brebi, P. M. & oa, J. C. Epigenetic alterations in preneoplastic and neoplastic lesions of the cervix. Clin Epigenetics
4, 13 (2012).
30. eating, J. T. et al. i-67, cyclin E, and p16IN4 are complimentary surrogate biomarers for human papilloma virus-related
cervical neoplasia. Am J Surg Pathol 25, 884–891 (2001).
31. Loer, D. et al. Interleuin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microNA-21
through a highly conserved enhancer. Blood 110, 1330–1333 (2007).
32. Wang, X. et al. Mi-214 inhibits cell growth in hepatocellular carcinoma through suppression of beta-catenin. Biochem Biophys es
Commun 428, 525–531 (2012).
33. Xu, L. F. et al. MicroNA-21 (mi-21) regulates cellular proliferation, invasion, migration, and apoptosis by targeting PTEN, EC
and Bcl-2 in lung squamous carcinoma, Gejiu City, China. PLoS One 9, e103698 (2014).
34. Shen, H. et al. Alteration in Mir-21/PTEN expression modulates getinib resistance in non-small cell lung cancer. PLoS One 9,
e103305 (2014).
35. oss, A. H. & Gerice, A. Phosphorylation eeps PTEN phosphatase closed for business. Proc Natl Acad Sci USA 106, 1297–1298
36. Maccario, H., Perera, N. M., Davidson, L., Downes, C. P. & Leslie, N. . PTEN is destabilized by phosphorylation on r366.
Biochem J 405, 439–444 (2007).
37. Xia, H., Ooi, L. L. & Hui, . M. Mi-214 targets beta-catenin pathway to suppress invasion, stem-lie traits and recurrence of human
hepatocellular carcinoma. PLoS One 7, e44206 (2012).
38. Wang, Y., Zhai, W., Wang, H., Xia, X. & Zhang, C. Benzo(a)pyrene promotes A549 cell migration and invasion through up-
regulating Twist. Arch Toxicol, 89(3), 451–458 (2015).
39. Castillo-Sanchez, ., Villegas-Comonfort, S., Galindo-Hernandez, O., Gomez, . & Salazar, E. P. Benzo-[a]-pyrene induces FA
activation and cell migration in MDA-MB-231 breast cancer cells. Cell Biol Toxicol 29, 303–319 (2013).
40. Yoshino, I. et al. Induction of epithelial-mesenchymal transition-related genes by benzo[a]pyrene in lung cancer cells. Cancer 110,
369–374 (2007).
41. Li, F., Wang, T. & Tang, S. SOX14 promotes proliferation and invasion of cervical cancer cells through Wnt/β -catenin pathway. Int J
Clin Exp Pathol 8(2), 1698–1704 (2015).
42. Polais, P. e many ways of Wnt in cancer. Curr Opin Genet Dev 17, 45–51 (2007).
43. MacDonald, B. T., Tamai, . & He, X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 17, 9–26 (2009).
44. Henderson, B. . & Fagotto, F. e ins and outs of APC and beta-catenin nuclear transport. EMBO ep 3, 834–839 (2002).
45. Cadigan, . M. & Peifer, M. Wnt signaling from development to disease: insights from model systems. Cold Spring Harb Perspect Biol
1, a002881 (2009).
46. Jamieson, C., Sharma, M. & Henderson, B. . Wnt signaling from membrane to nucleus: beta-catenin caught in a loop. Int J Biochem
Cell Biol 44, 847–850 (2012).
47. McGraw, S. L. & Ferrante, J. M. Update on prevention and screening of cervical cancer. World J Clin Oncol 5, 744–752 (2014).
Scientific RepoRts | 6:20051 | DOI: 10.1038/srep20051
48. Schiman, M., Castle, P. E., Jeronimo, J., odriguez, A. C. & Wacholder, S. Human papillomavirus and cervical cancer. Lancet 370,
890–907 (2007).
49. McIntyre-Seltman, ., Castle, P. E., Guido, ., Schiman, M., Wheeler, C. M. & Group, A. Smoing is a ris factor for cervical
intraepithelial neoplasia grade 3 among oncogenic human papillomavirus DNA-positive women with equivocal or mildly abnormal
cytology. Cancer Epidemiol Biomarers Prev 14, 1165–1170 (2005).
50. Izzotti, A. et al. Downregulation of microNA expression in the lungs of rats exposed to cigarette smoe. FASEB J 23, 806–812
51. Schembri, F. et al. MicroNAs as modulators of smoing-induced gene expression changes in human airway epithelium. Proc Natl
Acad Sci USA 106, 2319–2324 (2009).
52. Chen, W. et al. Low-dose gamma-irradiation inhibits IL-6 secretion from human lung broblasts that promotes bronchial epithelial
cell transformation by cigarette-smoe carcinogen. Carcinogenesis 33, 1368–1374 (2012).
53. Pei, X. H. et al. Polycyclic aromatic hydrocarbons induce IL-8 expression through nuclear factor appaB activation in A549 cell line.
Cytoine 19, 236–241 (2002).
54. Volinia, S. et al. A microNA expression signature of human solid tumors denes cancer gene targets. Proc Natl Acad Sci USA 103,
2257–2261 (2006).
55. Shin, V. Y. et al. NF-appaB targets mi-16 and mi-21 in gastric cancer: involvement of prostaglandin E receptors. Carcinogenesis
32, 240–245 (2011).
56. Zhou, ., Hu, G., Gong, A. Y. & Chen, X. M. Binding of NF-appaB p65 subunit to the promoter elements is involved in LPS-
induced transactivation of miNA genes in human biliary epithelial cells. Nucleic Acids es 38, 3222–3232 (2010).
57. Di, G. H. et al. IL-6 secreted from senescent mesenchymal stem cells promotes proliferation and migration of breast cancer cells.
PLoS One 9, e113572 (2014).
58. Sun, W. et al. Interleuin-6 promotes the migration and invasion of nasopharyngeal carcinoma cell lines and upregulates the
expression of MMP-2 and MMP-9. Int J Oncol 44, 1551–1560 (2014).
59. Heinece, J. L. et al. Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression. Proc Natl Acad
Sci USA 111, 6323–6328 (2014).
60. Punfa, W., Yodeeree, S., Pitchaarn, P., Ampasavate, C. & Limtraul, P. Enhancement of cellular uptae and cytotoxicity of
curcumin-loaded PLGA nanoparticles by conjugation with anti-P-glycoprotein in drug resistance cancer cells. Acta Pharmacol Sin
33(6), 823–31 (2012).
is work was supported by the NIH U01CA162106, R01CA142736, K22 CA174841; Department of Defense
ARMY GRANT W81XWH-14-1-0154; and College of Pharmacy/University of Tennessee Health Science Center
Seed Grant.
Author Contributions
M.S.Z designed and performed experiments (proliferation assays, animal experiments, RT-PCR experiments and
analysis, confocal microscopy, ISH and IHC), analyzed data and wrote the paper; N.C. performed experiments
(uptake, clonogenic and proliferation assays, ow cytometry experiments, IHC), data analysis, gure preparation,
participated in method section writing and manuscript editing; R.K.G. performed experiments (Western blots,
IL-6 measurement and migration assay); D.M.M. designed experiments and analyzed data; S.K. performed
experiments (IL-6 measurement and migration assay); M.S. participated in animal experiments; S.K. performed
and analyzed ISH experiments; M.M.Y. synthesized Nano-CUR, analyzed data, participated in animal
experiments, prepared gures, wrote the parts of manuscript, drew Figure 7, and edited the manuscript; N.Z. was
involved as a pathologist and oversee the IHC and ISH studies, M.J. and S.C.C. conceived the idea, analyzed data,
and edited the manuscript.
Additional Information
Competing nancial interests: e authors declare no competing nancial interests.
How to cite this article: Zaman, M. S. et al. Curcumin Nanoformulation for Cervical Cancer Treatment.
Sci. Rep. 6, 20051; doi: 10.1038/srep20051 (2016).
is work is licensed under a Creative Commons Attribution 4.0 International License. e images
or other third party material in this article are included in the article’s Creative Commons license,
unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license,
users will need to obtain permission from the license holder to reproduce the material. To view a copy of this
license, visit
... Recent proteomic studies have shown that curcumin causes significant changes in proteins associated with cell metabolism, cell cycle, and carcinogenesis in HeLa cells. The decrease in cervical tumor volume has also been demonstrated in the curcumin-treated mouse model (21). ...
... In line with our findings, another type of nano-curcumin (poly (lactic-co-glycolic acid) based curcumin nanoparticle formulation) has been applied to apoptosis induction in cervical cancer. Results indicated that this type of nanocurcumin effectively inhibits the growth of cervical cancer cell lines in 20 µM and 25 µM, abrogates expression of E6 and E7 oncogenes, and leads them to apoptosis (21). ...
Full-text available
Background: Curcumin, a compound derived from the root of the Curcuma longa, has been confirmed as an anticancer, chemoprotective, and gene/protein regulatory agent. Nanoformulation of curcumin has been developed to increase its targeting efficiency, solubility, controlled release, and physical and chemical stability. Objectives: This study investigated the effect of new nano-type curcumin, oleic acid-derived dendrosome (OA400 nanoparticles), on the expression of E6 and E7 human papillomavirus oncogenes and P53 and Rb factors in the HeLa cell line. After preparing nano-curcumin by mixing OA400 nano-carrier and curcumin, its effect was considered on the human cervical cancer cell line (HeLa cell line RRID: CVCL_003) and normal fibroblast cells. Methods: MTT assay and flow cytometry were used to evaluate cell viability and apoptosis. Furthermore, real-time RT-PCR and western blot analyses assessed RNA and protein expression of E6, E7, P53, and Rb. Statistical analyses were performed by GraphPad Prism 7 software. Results: The nanoformulation of curcumin could reduce the expression of E6 and E7 oncogenes and increase P53 and Rb tumor suppressors in HeLa cancerous cells at 15 μM concentration; however, it had no significant effect on the viability of normal fibroblast cells. On the other hand, curcumin altered the expression of these genes at a 50-μM concentration. Gene and protein expression analysis indicated the up-regulation of P53 and Rb factors and the down-regulation of E6 and E7 under the influence of nano-curcumin treatment more than curcumin. Conclusions: These data indicate the potential of curcumin-loaded OA400 nanoparticles to be considered as a treatment option in cervical cancer investigations.
... Multiple studies have demonstrated the effects of turmeric against cancer cells in vitro [103][104][105], and a recent review by Kabir discusses the effectiveness of newer formulations of turmeric against multiple cancer types including HNC [106]. Because turmeric absorption is poor, recent research has focused on how to incorporate turmeric into chemotherapy [107][108][109]. Farghadani and Naidu reviewed recent studies and human trials on curcumin effects in breast cancer [110], and Chen reported that curcumin analog HO-3867 activates JNK1/2 signaling in human oral squamous cell cancer cells [111]. ...
Full-text available
Patients and providers may not be aware that several adjunctive measures can significantly improve the quality of life, response to treatment, and possibly outcomes for cancer patients. This manuscript presents a review of practical under-recognized adjunctive therapies that are effective including exercise; stress-reduction techniques such as mindfulness, massage, yoga, Tai Chi, breathing exercises; importance of sleep quality; diet modifications such as calorie restriction at the time of chemotherapy and avoidance of high carbohydrate foods; supplements such as aspirin, green tea, turmeric, and melatonin; and repurposed prescription medications such as metformin and statins. Each recommendation should be tailored to the individual patient to assure no contraindications.
... It is widely acknowledged that resistance to chemo/radio-therapies; prolonged treatment, therapeutic effect and prognosis are the area of intense clinical research Zaman et al. 2016). Facing increasing challenges in resistance to chemotherapies, rapid evolution of biotechnology is likely to have an important in uence on medicine to alleviate the crisis. ...
Full-text available
Cervical cancer is the fourth most common cause of cancer-related death among women globally. Microbial products represent an available source of anticancer drugs. Thus, this study aimed to extract the total protein from Candida species (CanSp) and subsequently investigate its inhibitory effects against human cervical cancer HeLa cells. This study reports the five total protein of the yeast-to-hyphal transition culture of Candida species, which were then evaluated for their inhibitory potential by cell viability, cell apoptosis and nitrite assays against HeLa cells. Furthermore, transcriptional profile of OCT4B gene was determined using quantitative reverse transcription PCR. Total protein of CanSp1-5 were obtained from Candida species. The result of the protein quantitation assay indicated that the CanSp1-5 exhibited total protein values from 93.72 to 155.25 µg/mL and 89.88 to 144.33 µg/mL by Bradford and micro-Kjeldahl methods, respectively. The CanSp1 was most active with a half-maximal inhibitory concentration of 157.11 ± 0.001 μg/mL and half-maximal effective concentration of 102 ± 0.001 μg/mL. The distinct morphological changes of cells were showed a typical apoptosis. Moreover, a reduction in the nitric oxide concentration was observed in the HeLa cells. The expression level of OCT4B gene was significantly down regulated in the HeLa cells treated with CanSp1-5 . These findings highlight the importance of investigating microbial products for the accelerated development new anticancer drugs. In addition, OCT4B gene could be probable molecular target of the CanSp1-5 in the HeLa cells.
The use of nanotechnological products is increasing steadily. In this scenario, the application of nanotechnology in food science and as a technological platform is a reality. Among the several applications, the main use of this technology is for the development of foods and nutraceuticals with higher bioavailability, lower toxicity, and better sustainability. In the health field, nano-nutraceuticals are being used as supplementary products to treat an increasing number of diseases. This review summarizes the main concepts and applications of nano-nutraceuticals for health, with special focus on treating cancer and inflammation.Graphical abstract
Full-text available
There is increasing evidence suggesting the role of microbiome alterations in relation to pancreatic adenocarcinoma and tumor immune functionality. However, molecular mechanisms of the interplay between microbiome signatures and/or their metabolites in pancreatic tumor immunosurveillance are not well understood. We have identified that a probiotic strain (Lactobacillus casei) derived siderophore (ferrichrome) efficiently reprograms tumor-associated macrophages (TAMs) and increases CD8 + T cell infiltration into tumors that paralleled a marked reduction in tumor burden in a syngeneic mouse model of pancreatic cancer. Interestingly, this altered immune response improved anti-PD-L1 therapy that suggests promise of a novel combination (ferrichrome and immune checkpoint inhibitors) therapy for pancreatic cancer treatment. Mechanistically, ferrichrome induced TAMs polarization via activation of the TLR4 pathway that represses the expression of iron export protein ferroportin (FPN1) in macrophages. This study describes a novel probiotic based molecular mechanism that can effectively induce anti-tumor immunosurveillance and improve immune checkpoint inhibitors therapy response in pancreatic cancer.
Full-text available
Kan Glukoz Değerlerinin Patolojik Değişimleri
Renal cell carcinoma (RCC) is one of the most common kidney cancers, responsible for nearly 90 % of all renal malignancies. Despite the availability of many treatment strategies, RCC still remains to be an incurable disease due to its resistivity towards conventional therapies. Nanotechnology is an emerging field of science that offers newer possibilities in therapeutics including cancer medicine, specifically by targeted delivery of anticancer drugs. Several phytochemicals are known for their anti-cancer properties and have been regarded as chemopreventive agents. However, the hydrophobic nature of many phytochemicals decreases its bioavailability and distribution, thus showing limited therapeutic effect. Application of nanotechnology to enhance chemoprevention is an effective strategy to increase the bioavailability of phytochemicals and thereby its therapeutic efficacy. The present review focuses on the utility of nanotechnology in RCC treatment and chemopreventive agents of RCC. We have also visualized the future prospects of nanomolecules in the prevention and cure of RCC.
Full-text available
Autism spectrum disorder (ASD) is defined as a neurodevelopmental disorder which results in impairments in social communications and interactions as well as repetitive behaviors. Despite current estimates showing that approximately 2.2% of children are affected in the United States, relatively little about ASD pathophysiology is known in part due to the highly heterogenous presentation of the disorder. Given the limited knowledge into the biological mechanisms governing its etiology, the diagnosis of ASD is performed exclusively based on an individual’s behavior assessed by a clinician through psychometric tools. Although there is no readily available biochemical test for ASD diagnosis, multivariate statistical methods show considerable potential for effectively leveraging multiple biochemical measurements for classification and characterization purposes. In this work, markers associated with the folate dependent one‐carbon metabolism and transulfuration (FOCM/TS) pathways analyzed via both Fisher Discriminant Analysis and Support Vector Machine showed strong capability to distinguish between ASD and TD cohorts. Furthermore, using Kernel Partial Least Squares regression it was possible to assess some degree of behavioral severity from metabolomic data. While the results presented need to be replicated in independent future studies, they represent a promising avenue for uncovering clinically relevant ASD biomarkers.
Curcumin, a plant‐derived compound, has various well‐known biological effects (anti‐inflammatory, antioxidant, antitumor, among others) as well as some important limitations for formulators, such as poor water solubility and low oral bioavailability. Its nanoencapsulation is reported to overcome these drawbacks and to improve its in vivo efficacy. Here, data from preclinical in vivo studies evaluating the antitumor efficacy of curcumin‐loaded polymeric nanocapsules are collected, analyzed, and discussed as a systematic review. Meta‐analyses are performed to assess the contribution of this nanoencapsulation compared with nonencapsulated curcumin. Eighteen studies (116 animals) meet the inclusion criteria. The evidence that curcumin‐loaded polymeric nanocapsules inhibits tumor growth (SMD: −3.03; 95% CI: −3.84, −2.21; p < 0.00001) and decreases tumor weight (SMD: −3.96; 95% CI: −6.22, −1.70; p = 0.0006) in rodents is established, regardless of the solid tumor model. To assess the quality of the studies included in the review a bias risk analysis was performed using the SYRCLE's RoB tool. Therefore, encapsulation in polymeric nanocapsules represents an important tool to improve the antitumor effects of curcumin, and this systematic review paves the way for future clinical studies and the translation of curcumin formulations into novel nanomedicines for human cancer treatment.
Full-text available
Human mesenchymal stem cells (hMSCs) are currently investigated for a variety of therapeutic applications. However, MSCs isolated from primary tissue cannot meet clinical grade needs and should be expanded in vitro for several passages. Although hMSCs show low possibility for undergoing oncogenic transformation, they do, similar to other somatic cells, undergo cellular senescence and their therapeutic potential is diminished when cultured in vitro. However, the role of senescent MSCs in tumor progression remains largely elusive. In the current study, by establishing senescent human umbilical cord mesenchymal stem cells (s-UCMSCs) through the replicative senescence model and genotoxic stress induced premature senescence model, we show that s-UCMSCs significantly stimulate proliferation and migration of breast cancer cells in vitro and tumor progression in a co-transplant xenograft mouse model compared with 'young' counterparts (defined as MSCs at passage 5, in contrast to senescent MSCs at passage 45). In addition, we identified IL-6, a known pleiotropic cytokine, as a principal mediator for the tumor-promoting activity of s-UCMSCs by induction of STAT3 phosphorylation. Depletion of IL-6 from s-UCMSCs conditioned medium partially abrogated the stimulatory effect of s-UCMSCs on the proliferation and migration of breast tumor cells.
Full-text available
MicroRNA-21 (miR-21) has been suggested to play a significant role in the prognosis of carcinoma. The recognition of novel biomarkers for the prediction of cancer outcomes is urgently required. However, the potential prognostic value of miR-21 in various types of human malignancy remains controversial. The present meta-analysis summarises and analyses the associations between miR-21 status and overall survival (OS) in a variety of tumours. Eligible published studies were identified by searching the PubMed and Chinese Biomedicine databases. The patients’ clinical characteristics and survival results were pooled, and a pooled hazard ratio (HR) with 95% confidence intervals (95% CI) was used to calculate the strength of this association. A random-effects model was adopted, and then, meta-regression and subgroup analyses were performed. In addition, an analysis of publication bias was also conducted. Twenty-seven eligible articles (including 31 studies) were identified that included survival data for 3273 patients. The pooled HR suggested that high miR-21 was clearly related to worse overall survival (HR = 2.27, 95% CI: 1.81-2.86), with a heterogeneity measure index of I2 = 76.0%, p = 0.001, showing that miR-21 might be a considerable prognostic factor for poor survival in cancer patients. MiR-21 might be a potentially useful biomarker for predicting cancer prognosis in future clinical applications.
Full-text available
Cervical cancer is the third most common cause of cancer in women in the world. During the past few decades tremendous strides have been made toward decreasing the incidence and mortality of cervical cancer with the implementation of various prevention and screening strategies. The causative agent linked to cervical cancer development and its precursors is the human papillomavirus (HPV). Prevention and screening measures for cervical cancer are paramount because the ability to identify and treat the illness at its premature stage often disrupts the process of neoplasia. Cervical carcinogenesis can be the result of infections from multiple high-risk HPV types that act synergistically. This imposes a level of complexity to identifying and vaccinating against the actual causative agent. Additionally, most HPV infections spontaneously clear. Therefore, screening strategies should optimally weigh the benefits and risks of screening to avoid the discovery and needless treatment of transient HPV infections. This article provides an update of the preventative and screening methods for cervical cancer, mainly HPV vaccination, screening with Pap smear cytology, and HPV testing. It also provides a discussion of the newest United States 2012 guidelines for cervical cancer screening, which changed the age to begin and end screening and lengthened the screening intervals.
Full-text available
Pancreatic ductal adenocarcinoma (PDAC) is an extremely severe disease where the mortality and incidence rates are almost identical. This is mainly due to late diagnosis and limited response to current treatments. The tumor macroenvironment/microenvironment have been frequently reported as the major contributors to chemoresistance in PDAC, preventing the drugs from reaching their intended site of action (i.e., the malignant duct cells). However, the recent discovery of microRNAs (miRNAs) has provided new directions for research on mechanisms underlying response to chemotherapy. Due to their tissue-/disease-specific expression and high stability in tissues and biofluids, miRNAs represent new promising diagnostic and prognostic/predictive biomarkers and therapeutic targets. Furthermore, several studies have documented that selected miRNAs, such as miR-21 and miR-34a, may influence response to chemotherapy in several tumor types, including PDAC. In this review, we summarize the current knowledge on the role of miRNAs in PDAC and recent advances in understanding their role in chemoresistance through multiple molecular mechanisms.
Full-text available
Background: In South China (Gejiu City, Yunnan Province), lung cancer incidence and associated mortality rate is the most prevalent and observed forms of cancer. Lung cancer in this area is called Gejiu squamous cell lung carcinoma (GSQCLC). Research has demonstrated that overexpression of miR-21 occurs in many cancers. However, the unique relationship between miR-21 and its target genes in GSQCLC has never been investigated. The molecular mechanism involved in GSQCLC must be compared to other non-small cell lung cancers in order to establish a relation and identify potential therapeutic targets. Methodology/principal findings: In the current study, we initially found overexpression of miR-21 occurring in non-small cell lung cancer (NSCLC) cell lines when compared to the immortalized lung epithelial cell line BEAS-2B. We also demonstrated that high expression of miR-21 could increase tumor cell proliferation, invasion, viability, and migration in GSQCLC cell line (YTMLC-90) and NSCLC cell line (NCI-H157). Additionally, our results revealed that miR-21 could suppress YTMLC-90 and NCI-H157 cell apoptosis through arresting cell-cycle at G2/M phase. Furthermore, we demonstrated that PTEN, RECK and Bcl-2 are common target genes of miR-21 in NSCLC. Finally, our studies showed that down-regulation of miR-21 could lead to a significant increase in PTEN and RECK and decrease in Bcl-2 at the mRNA and protein level in YTMLC-90 and NCI-H157 cell lines. However, we have not observed any remarkable difference in the levels of miR-21 and its targets in YTMLC-90 cells when compared with NCI-H157 cells. Conclusions/significance: miR-21 simultaneously regulates multiple programs that enhance cell proliferation, apoptosis and tumor invasiveness by targeting PTEN, RECK and Bcl-2 in GSQCLC. Our results demonstrated that miR-21 may play a vital role in tumorigenesis and progression of lung squamous cell carcinoma and suppression of miR-21 may be a novel approach for the treatment of lung squamous cell carcinoma.
Full-text available
Resistance to TKI treatment is a major obstacle in effective treatment of NSCLC. Besides EGFR mutation status, the mechanisms involved are largely unknown. Some evidence supports a role for microRNA 21 in modulating drug sensitivity of chemotherapy but its role in NSCLC TKI resistance still remains unexplored. This study aimed to investigate whether NSCLC miR-21 mediated resistance to TKIs also results from Pten targeting. Here, we show miR-21 promotes cancer by negatively regulating Pten expression in human NSCLC tissues: high miR-21 expression levels were associated with shorter DFS in 47 NSCLC patients; high miR-21/low Pten expression levels indicated a poor TKI clinical response and shorter overall survival in another 46 NSCLC patients undergoing TKI treatment. In vitro assays showed that miR-21 was up-regulated concomitantly to down-regulation of Pten in pc-9/GR cells in comparison with pc-9 cells. Moreover, over-expression of miR-21 significantly decreased gefitinib sensitivity by down-regulating Pten expression and activating Akt and ERK pathways in pc-9 cells, while miR-21 knockdown dramatically restored gefitinib sensitivity of pc-9/GR cells by up-regulation of Pten expression and inactivation of AKT and ERK pathways, in vivo and in vitro. We propose alteration of miR-21/Pten expression as a novel mechanism for TKI resistance in NSCLC cancer. Our findings provide a new basis for using miR 21/Pten-based therapeutic strategies to reverse gefitinib resistance in NSCLC.
Full-text available
Significance More than 92% of ER ⁻ breast cancer patients die with moderate to high NOS2. In this report, we show that tumor cell NOS2, through formation of a specific flux of NO, drives ER ⁻ disease to a more aggressive phenotype. Correlation between NOS2-related genes from patient cohorts, in vitro, and animal experiments show an inflammatory loop mediated by NOS2 that makes ER ⁻ breast cancer an aggressive disease.
SOX14 is a member of the SOXB2 subgroup of transcription factors implicated in neural development. Although SOX14 expression profile and function during development was revealed in various animal model systems, the role of this gene during tumor progression is totally unknown. In this study, the expression of SOX14 increases in four cervical cancer cell lines (HeLa, Caski, HT-3 and SiHa) as revealed by real-time PCR and Western blot analyses. Through knocking down or overexpressing SOX14 in SiHa and HeLa cells, the expression level of SOX14 was found to be positively related to cell proliferation and invasion in vitro. Moreover, the TOP-Flash reporter assay and Western blot for β-catenin genes of the Wnt/β-catenin pathway, indicated that SOX14 significantly activated Wnt/β-catenin signaling. Further study showed that the blockage of Wnt/β-catenin pathway by knocking down β-catenin resulted in a significant inhibition of cell proliferation and invasion capacity induced by SOX14. To summarize, these results demonstrate that SOX14 can promote proliferation and invasion capacity of cervical cancer cells by activating the Wnt/β-catenin pathway.
Benzo(a)pyrene (BaP) is one of the strongest carcinogens in cigarette smoke, which is an established human carcinogen. Twist, a transcription factor of the basic helix-loop-helix class, is reported to regulate lung cancer metastasis. Evidence has shown that BaP could induce Twist mRNA expression in non-small cell lung cancer (NSCLC) cell line A549 and promote lung adenocarcinoma cell invasion. However, it is unclear whether BaP promotes the migration and invasion of NSCLC cells by Twist modulation. A549 cell was exposed to BaP for different time. MTT assay was applied to assess cell proliferation. Silencing of Twist was done by small interfering RNA. Wound-healing assay was used to evaluate the capability of cell migration. Transwell assay was used to detect the capability of cell invasion. Western blotting and quantitative polymerase chain reaction were used to detect Twist expression. The levels of Twist protein expression and mRNA expression were increased with the treatment of BaP, compared with solvent control. The capability of wound healing of A549 cells was increased in BaP-treated group, compared with solvent control. BaP enhanced the capability of invasion of A549 cells. Twist knockdown could block the migration and invasion of A549 cells induced by BaP treatment. The mRNA levels of Twist were higher in metastatic NSCLC tissue samples than in primary NSCLC tissue samples, and higher levels of Twist mRNA were observed in metastatic NSCLC tissue samples with smoking history than in those with nonsmoking history. BaP treatment could promote the migration and invasion of NSCLC cells by up-regulating Twist expression.
Nasopharyngeal carcinoma (NPC) shows the highest invasive and metastatic features among head and neck cancers. Distant metastasis remains the predominant mode of treatment failure in NPC patients. The role of interleukin-6 (IL-6) in NPC progression is not fully understood. In this study, we explored whether IL-6 could promote the migration and invasion activity of NPC cell lines, as well as whether the effect of IL-6 on cell migration and invasion is mediated through regulating the expression of matrix metalloproteinase-2 (MMP-2) and MMP-9. Our results revealed that IL-6 and its receptors are broadly expressed in various NPC cell lines including HNE1, HONE1, CNE1, CNE1-LMP1 and 5-8F. Exogenous IL-6 enhanced cell proliferation slightly, but promoted cell migration and invasion significantly in both HNE1 and CNE1-LMP1 cell lines. In addition, an elevation in the expression of MMP-2 and MMP-9 could be induced by IL-6 stimulation. On the contrary, combining treatment with monoclonal anti-human IL-6R antibody (anti-IL-6R mAb) resulted in decreased proliferation, migration and invasion capabilities of NPC cells. Anti-IL-6R mAb also inhibited the expression of MMP-2 and MMP-9 in IL-6-stimulated HNE1 and CNE1-LMP1 cells. In summary, our data suggested that IL-6 mainly promotes the cell migration and invasion of NPC cells. The effect of IL-6 on cell migration and invasion may be mediated through regulation of the expression of MMP-2 and MMP-9. Thus, IL-6 or its related signaling pathways may be a promising target for preventing and inhibiting NPC metastasis.